Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Surgery. 2020 Jun 29;169(1):155–161. doi: 10.1016/j.surg.2020.04.034

Figure 1. Somatostatin expression is lower in PNET metastases compared to primary tumors.

Figure 1

(a) Comparison of somatostatin expression in primary PNETs, nodal metastases, and hepatic metastases from 43 patients by RNA sequencing. (b) Comparison of somatostatin expression between matched primary and hepatic metastases (n = 16) by RNA sequencing from the same cohort of patients as in (a). (c-f) Comparison of gene expression in primary PNETs and hepatic metastases by qPCR in a different validation cohort of 12 patients for somatostatin (c), somatostatin receptor 2 (d), synaptophysin (e), and chromogranin A (f). * p < .05

Abbreviations: lymph node (LN), metastasis (met), pancreatic neuroendocrine tumor (PNET)